MX337421B - Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. - Google Patents
Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida.Info
- Publication number
- MX337421B MX337421B MX2010006593A MX2010006593A MX337421B MX 337421 B MX337421 B MX 337421B MX 2010006593 A MX2010006593 A MX 2010006593A MX 2010006593 A MX2010006593 A MX 2010006593A MX 337421 B MX337421 B MX 337421B
- Authority
- MX
- Mexico
- Prior art keywords
- adp
- poly
- present
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical class N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012623 DNA damaging agent Substances 0.000 abstract 1
- 230000033616 DNA repair Effects 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1033308P | 2008-01-08 | 2008-01-08 | |
| PCT/GB2009/000041 WO2009087381A1 (en) | 2008-01-08 | 2009-01-08 | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2010006593A MX2010006593A (es) | 2010-12-21 |
| MX337421B true MX337421B (es) | 2016-03-04 |
Family
ID=40404013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010006593A MX337421B (es) | 2008-01-08 | 2009-01-08 | Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8436185B2 (https=) |
| EP (1) | EP2240466B1 (https=) |
| JP (1) | JP5989965B2 (https=) |
| KR (1) | KR101653548B1 (https=) |
| CN (2) | CN101932572A (https=) |
| AU (1) | AU2009203598B2 (https=) |
| BR (1) | BRPI0906020A2 (https=) |
| CA (1) | CA2711491C (https=) |
| ES (1) | ES2548131T3 (https=) |
| FR (1) | FR18C1020I2 (https=) |
| IL (1) | IL206201A (https=) |
| MX (1) | MX337421B (https=) |
| NL (1) | NL300938I2 (https=) |
| NZ (1) | NZ586675A (https=) |
| WO (1) | WO2009087381A1 (https=) |
| ZA (1) | ZA201003902B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2599458T3 (es) | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| EP2408300B1 (en) | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| EP4166558A1 (en) | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2017056498A1 (ja) * | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | 糖尿病性腎症の判定マーカー |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| UA124972C2 (uk) * | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
| CN107663190B (zh) * | 2016-07-29 | 2020-06-09 | 钟桂发 | 一种尼拉帕尼及其中间体的制备方法以及中间体化合物 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| CN110944638A (zh) * | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| EP3606524B1 (en) * | 2017-04-04 | 2021-12-01 | Combiphos Catalysts, Inc. | Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide |
| HUE060460T2 (hu) | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| CN108530425A (zh) * | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| CN109081828B (zh) | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| HUE062956T2 (hu) | 2017-08-14 | 2023-12-28 | Teva Pharmaceuticals Int Gmbh | Eljárások niraparib és köztitermékei elõállítására |
| CN111094981B (zh) * | 2017-09-13 | 2024-04-16 | B.R.A.H.M.S有限公司 | Pct和pro-adm作为监测抗生素治疗的标记物 |
| CA3075440A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Pro-adm as a therapy monitoring marker for critcally ill patients |
| US20200271666A1 (en) * | 2017-09-13 | 2020-08-27 | B.R.A.H.M.S Gmbh | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| US20210106574A1 (en) | 2017-12-27 | 2021-04-15 | Tesaro, Inc. | Methods of Treating Cancer |
| CN111918667A (zh) | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| JP2022504228A (ja) * | 2018-10-03 | 2022-01-13 | テサロ， インコーポレイテッド | ニラパリブ遊離塩基の結晶形態 |
| CN113166071B (zh) * | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
| WO2020072860A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| WO2020225753A2 (en) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN110407704B (zh) * | 2019-08-19 | 2022-05-17 | 常州沃腾化工科技有限公司 | 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法 |
| TWI905184B (zh) | 2020-05-08 | 2025-11-21 | 比利時商健生藥品公司 | 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌 |
| JP2024525881A (ja) | 2021-07-19 | 2024-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | ニラパリブ（ｎｉｒａｐａｒｉｂ）による転移性去勢抵抗性前立腺癌の治療 |
| CA3243120A1 (en) | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF) |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| CN121311226A (zh) | 2023-05-17 | 2026-01-09 | 特沙诺有限公司 | 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途 |
| WO2025027138A1 (en) | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
| CN117843713A (zh) * | 2023-12-18 | 2024-04-09 | 上海亲合力生物医药科技股份有限公司 | 基于肿瘤微环境激活的激酶抑制剂、组合物及应用 |
| CN119707921B (zh) * | 2024-12-19 | 2026-03-03 | 四川轻化工大学 | 一种尼拉帕尼的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| EP0841924B1 (en) | 1995-08-02 | 2002-10-02 | Newcastle University Ventures Limited | Benzimidazole compounds |
| CA2332279A1 (en) | 1998-05-15 | 1999-11-25 | Jia-He Li | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| EP1124805B1 (de) | 1998-10-30 | 2003-05-21 | Lonza AG | Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen |
| IL142917A0 (en) | 1998-11-03 | 2002-04-21 | Basf Ag | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| HRP20010451A2 (en) | 1998-11-17 | 2003-04-30 | Basf Ag | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| TR200101498T2 (tr) | 1998-11-27 | 2001-11-21 | Basf Aktiengesellschaft | İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6508365B1 (en) * | 1999-12-28 | 2003-01-21 | Pitney Bowes Inc. | Method of removing mail from a mailstream using an incoming mail sorting apparatus |
| DE50112961D1 (de) | 2000-02-01 | 2007-10-18 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003062234A1 (en) | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| JPWO2004014861A1 (ja) | 2002-08-09 | 2005-12-02 | 杏林製薬株式会社 | ４−置換キノリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| ATE411980T1 (de) * | 2003-07-21 | 2008-11-15 | Smithkline Beecham Corp | (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| WO2005066136A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
| PT1794163E (pt) | 2004-09-22 | 2010-03-01 | Pfizer | Método para a preparação de inibidores de poli(adpribose)- polimerases |
| EP1812439B2 (en) * | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| US7930013B2 (en) | 2005-06-29 | 2011-04-19 | Compumedics Limited | Sensor assembly with conductive bridge |
| JP5227796B2 (ja) | 2005-09-29 | 2013-07-03 | アボット・ラボラトリーズ | ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である |
| JP5162465B2 (ja) | 2005-11-15 | 2013-03-13 | アボット・ラボラトリーズ | 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である |
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| MX2008014004A (es) | 2006-05-02 | 2008-11-12 | Abbott Lab | 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US7892667B2 (en) * | 2006-09-13 | 2011-02-22 | Altek Corporation | Battery security device |
| JP4611444B2 (ja) * | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| JP2008228154A (ja) * | 2007-03-15 | 2008-09-25 | Fujitsu Ltd | 表示装置，および遠隔操作装置 |
-
2009
- 2009-01-08 KR KR1020107015011A patent/KR101653548B1/ko active Active
- 2009-01-08 AU AU2009203598A patent/AU2009203598B2/en active Active
- 2009-01-08 CN CN2009801018616A patent/CN101932572A/zh active Pending
- 2009-01-08 US US12/811,922 patent/US8436185B2/en active Active
- 2009-01-08 WO PCT/GB2009/000041 patent/WO2009087381A1/en not_active Ceased
- 2009-01-08 ES ES09700579.7T patent/ES2548131T3/es active Active
- 2009-01-08 EP EP09700579.7A patent/EP2240466B1/en active Active
- 2009-01-08 NZ NZ586675A patent/NZ586675A/en unknown
- 2009-01-08 CA CA2711491A patent/CA2711491C/en active Active
- 2009-01-08 CN CN201610345956.4A patent/CN106008460B/zh active Active
- 2009-01-08 JP JP2010541101A patent/JP5989965B2/ja active Active
- 2009-01-08 BR BRPI0906020-0A patent/BRPI0906020A2/pt not_active Application Discontinuation
- 2009-01-08 MX MX2010006593A patent/MX337421B/es active IP Right Grant
-
2010
- 2010-06-01 ZA ZA2010/03902A patent/ZA201003902B/en unknown
- 2010-06-06 IL IL206201A patent/IL206201A/en active Protection Beyond IP Right Term
-
2018
- 2018-05-14 FR FR18C1020C patent/FR18C1020I2/fr active Active
- 2018-05-15 NL NL300938C patent/NL300938I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100114021A (ko) | 2010-10-22 |
| KR101653548B1 (ko) | 2016-09-02 |
| ZA201003902B (en) | 2011-02-23 |
| CN106008460A (zh) | 2016-10-12 |
| CA2711491A1 (en) | 2009-07-16 |
| IL206201A (en) | 2014-07-31 |
| JP5989965B2 (ja) | 2016-09-07 |
| CN101932572A (zh) | 2010-12-29 |
| FR18C1020I1 (https=) | 2018-07-13 |
| AU2009203598B2 (en) | 2013-09-26 |
| US8436185B2 (en) | 2013-05-07 |
| CN106008460B (zh) | 2022-08-12 |
| US20100286203A1 (en) | 2010-11-11 |
| EP2240466A1 (en) | 2010-10-20 |
| BRPI0906020A2 (pt) | 2015-06-30 |
| ES2548131T3 (es) | 2015-10-14 |
| RU2010133241A (ru) | 2012-02-20 |
| IL206201A0 (en) | 2010-12-30 |
| NZ586675A (en) | 2012-04-27 |
| NL300938I2 (nl) | 2019-01-08 |
| CA2711491C (en) | 2016-03-08 |
| EP2240466B1 (en) | 2015-07-29 |
| AU2009203598A1 (en) | 2009-07-16 |
| RU2495035C2 (ru) | 2013-10-10 |
| JP2011509252A (ja) | 2011-03-24 |
| WO2009087381A1 (en) | 2009-07-16 |
| FR18C1020I2 (fr) | 2019-06-07 |
| MX2010006593A (es) | 2010-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337421B (es) | Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. | |
| MX2009013077A (es) | Derivados dde benzoxazolona. | |
| WO2010108187A3 (en) | Compounds and methods for treating mammalian gastrointestinal microbial infections | |
| PH12013501772A1 (en) | Inhibitors of e1 activating enzyme | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| MY157177A (en) | Heteroaryl compounds useful as inhibitors of e1 activating enzymes | |
| NZ603525A (en) | Pyrimidine based compound and uses thereof | |
| MX2009013341A (es) | Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. | |
| MX2009009948A (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa. | |
| GEP20125564B (en) | Pyrimidine derivatives as kinase inhibitors | |
| UA99311C2 (en) | Inhibitors of c-fms kinase | |
| MX2009012708A (es) | Derivados de piridazinona. | |
| MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| MX2010005343A (es) | Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina. | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| NZ592925A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| UA100540C2 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| NZ702050A (en) | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| EA200901603A1 (ru) | Арил-эфирные производные пиридазинона | |
| ECSP10010411A (es) | INHIBIDORES HETEROCÍCLICOS DE ESTEAROIL-CoA-DESATURASA | |
| BRPI0506802A (pt) | derivados de indol e uso destes como inibidores de quinase em inibidores de ikk2 particulares | |
| MX2011012629A (es) | Inhibidores de actividad de cinasa tipo pirimidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: MERCK SHARP & DOHME LTD. |
|
| HC | Change of company name or juridical status |
Owner name: MERCK SHARP & DOHME LTD. |
|
| FG | Grant or registration |